Superior PFS with sotorasib in colorectal cancer
Metastatic colorectal cancer (CRC) patients with KRAS (G12C) mutations benefit from sotorasib plus panitumumab Kirsten rat sarcoma viral oncogene homologs are present in approximately 3% of all metastatic colorectal tumors (class) gly12-to-cys (G12C) mutation. Associated with poor prognosis.1 Sotorasib is a selective KRAS inhibitor that targets proteins derived from KRAS. class (G12C) mutation. In the […]
Sotorasib and panitumumab named new standard of care for metastatic colorectal cancer
The combination of sotorasib and panitumumab outperformed researchers’ treatment of choice in a phase 3 trial in chemotherapy-resistant patients. classG12C– Mutant metastatic colorectal cancer (CRC). Researchers tested the combination with two different doses of sotorasib and found that both doses improved progression-free survival (PFS). However, outcomes were better with higher doses of sotorasib. “The combination […]